| Phase 14 trials |
|
Phase 1
|
NCT04639843 |
Nov 2022 |
adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, extranodal nasal NK/T cell lymphoma, hepatosplenic T-cell lymphoma +1 |
National Cancer Institute (NCI) |
Withdrawn
|
No outcome recorded
|
|
Phase 1
|
NCT04887857 |
Dec 2021 → Jan 2024 |
acute myeloid leukemia |
Celgene Corporation |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02512172 |
Feb 2016 → Nov 2021 |
colorectal cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT01478685 |
Nov 2011 → Nov 2015 |
fallopian tube neoplasm, non-small cell lung carcinoma, ovarian neoplasm, pancreatic ductal adenocarcinoma +4 |
Celgene Corporation |
Completed
|
No outcome recorded
|
| Phase 1/22 trials |
|
Phase 1/2
|
NCT04722601 |
Sep 2021 → Mar 2023 |
follicular lymphoma |
University of Chicago |
Terminated
|
No outcome recorded
Stop: Business |
|
Phase 1/2
|
NCT01835587 |
Oct 2013 → Nov 2016 |
acute myeloid leukemia, myelodysplastic syndrome |
Celgene Corporation |
Completed
|
No outcome recorded
|
| Phase 210 trials · 3 missed |
|
Phase 2
|
NCT05413018 |
Aug 2022 → Oct 2025 overdue |
acute myeloid leukemia |
Bristol-Myers Squibb |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04806906 |
Mar 2021 → Jan 2025 |
chronic myelomonocytic leukemia, myelodysplastic syndrome |
University of Florence |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04174196 |
Nov 2019 → Nov 2026 expected |
plasma cell myeloma, plasmacytoma |
Memorial Sloan Kettering Cancer Center |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT03542266 |
Jun 2018 → Mar 2020 |
peripheral T-cell lymphoma, not otherwise specified |
Weill Medical College of Cornell University |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02494258 |
Oct 2015 → Apr 2025 |
hematopoietic and lymphoid cell neoplasm |
Celgene Corporation |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02546986 |
Oct 2015 → Apr 2017 |
non-small cell lung carcinoma |
Celgene Corporation |
Completed
|
Missed primary
|
|
Phase 2
|
NCT02374099 |
Mar 2015 → Dec 2016 |
breast cancer |
Celgene Corporation |
Terminated
|
Missed primary
|
|
Phase 2
|
NCT02269943 |
Feb 2015 → Apr 2017 |
nasopharyngeal neoplasm |
Celgene Corporation |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02250326 |
Jan 2015 → Jul 2017 |
non-small cell lung carcinoma |
Celgene Corporation |
Completed
|
Missed primary
|
|
Phase 2
|
NCT01928576 |
Nov 2013 → Apr 2023 |
non-small cell lung carcinoma |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Completed
|
No outcome recorded
|
| Comparator or background therapy3 trials |
|
Phase 2
|
NCT04778410 Background |
Jun 2021 → Mar 2024 |
myeloid neoplasm |
Gilead Sciences |
Terminated
|
No outcome recorded
Stop: Business |
|
Phase 2
|
NCT02900560 Comparator |
Dec 2016 → May 2021 |
ovarian epithelial tumor |
Translational Research in Oncology |
Terminated
|
No outcome recorded
|
| — |
NCT03723135 Background |
— |
acute myeloid leukemia |
Celgene Corporation |
Approved for marketing
|
No outcome recorded
|